Quantify. Decide. Confirm.

The CathWorks FFRangio™ System quickly and precisely delivers the objective FFR guidance needed to optimize PCI therapy decisions for every patient.

Current PCI
Challenges

30% of patients indicated for stents by estimated visual assessment did not need to be treated with stents when evaluated with Fractional Flow Reserve1.

Visual

Estimated Visual Assessment

Intraprocedural PCI (percutaneous coronary intervention) decisions using conventional coronary angiography are still principally made via an estimated visual assessment today.

PCI Guidance

Advancing PCI Guidance and Decision-Making

The FAME study1 showed that coronary stent usage could be reduced by about one-third if PCI decisions are based on FFR (Fractional Flow Reserve) measurements instead of on angiography alone (2.7 vs. 1.9, P<0.001). The FAME study went on to show that these patients do better and have less complications.

Issues

Conventional FFR Issues

FFR provides objective data that is clearly beneficial in PCI decision-making. However, conventional wire-delivered FFR is still used in fewer than 20% of procedures because it requires an additional intervention, is associated with increased clinical risks, additional radiation exposure, and increased procedural costs.

THE SOLUTION

The CathWorks FFRangio Solution

CathWorks FFRangio System is the non-invasive FFR platform that quickly and precisely delivers objective multi-vessel physiologic measurements to cost-effectively optimize and confirm intraprocedural PCI therapy decisions.

CathWorks FRRangio Reduces Procedure Cost

HOW IT WORKS

CathWorks System Technology

The CathWorks System works in combination with the angiography system in your cath lab to provide objective, non-invasive FFR data for PCI decision-making.

Reduction in coronary stent usage

Intraprocedural

CathWorks FFRangio System provides objective FFR data for PCI decision-making during the angiography procedure.

Connects

Connects

The CathWorks System connects directly to the angiography system in your Cath Lab and objective intraprocedural data is displayed on the FFR 3D Dashboard.

Compatible

Compatible

The CathWorks System platform is compatible with most angiography systems including the four leading systems in the market today.

Digitizes

Digitizes

CathWorks FFRangio System digitizes and computes angiography images to provide objective data for PCI decision-making.

Multi-vessel

Multi-vessel

The CathWorks System provides multi-vessel data so you can evaluate the entire coronary tree in one color-coded 3D image.

Confirms

Confirms

CathWorks FFRangio System enables you to confirm revascularization and procedural efficacy post-PCI.

REGULATORY STATUS

  • European Union / CE: CathWorks FFRangio has a CE Mark.
  • United States FDA: CathWorks has completed enrollment in US FDA Trial and expects approval by end of 2018.
  • Japan PMDA: CathWorks is in the process of working with PMDA for a submission by year end 2018.